Russia’s Enteromix Cancer Vaccine Shows 100% Efficacy in Early Trials
Share
A groundbreaking announcement from Russia has captured global attention: the Enteromix cancer vaccine, developed using mRNA technology similar to that used in COVID-19 vaccines, has achieved 100% efficacy and safety in early human clinical trials. The personalized vaccine, designed to train a patient’s immune system to recognize and attack colorectal cancer cells, was developed through a collaboration between the National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology.
The trials involved 48 volunteers and were presented at the 2025 St. Petersburg International Economic Forum as a potential game-changer in oncology. Results reportedly included complete tumor regression and no serious adverse effects—an outcome that, if verified through larger, randomized studies, could shift the paradigm in cancer treatment.
Enteromix’s breakthrough is especially significant given its personalized nature—each vaccine is tailored to a patient’s tumor antigen profile—and its highly favorable safety profile compared to conventional treatments such as chemotherapy and radiation.
However, caution is advised. Experts note that Phase I trials are primarily designed to assess safety, and results from a sample of 48 patients are too limited to draw definitive conclusions. No peer-reviewed data or long-term survival metrics have been published yet. Broader studies are needed to establish the vaccine’s efficacy, durability, and real-world impact.
If validated, Enteromix could herald a new era of personalized cancer immunotherapy—offering a targeted, effective, and less invasive alternative to traditional cancer treatments.
